News Chart Tourmaline Bio, Inc.

Equities

TRML

US89157D1054

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-22 EDT			5-day change	1st Jan Change
13.63 ^USD	-2.85%		-10.62%	-47.94%

05-16	Tourmaline Bio, Inc Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial	CI
05-13	Tourmaline Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

7ad5dafe7494eeb41cdc51a8adc8dc._e3JTeHi7geiqgQL5u3rN7HxdA9ICczipYVJXm0HdPo.l4CmJZeQukvM2GV-rqPcQ8iXOT8gToKIld8mKQgqEKmJ1bgAgralUPHpNA~269da8d6307b9bfc2657961064084fcf